KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $6.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Asset Writedowns and Impairment rose 5414.81% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Dec 2025, up 5414.81%, and an annual FY2025 reading of $6.0 million, up 5414.81% over the prior year.
  • Asset Writedowns and Impairment was $6.0 million for Q1 2025 at Recursion Pharmaceuticals, up from $108000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $6.0 million in Q1 2025 and bottomed at $19000.0 in Q3 2023.
  • Average Asset Writedowns and Impairment over 4 years is $2.0 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Asset Writedowns and Impairment crashed 90.76% in 2024, then skyrocketed 5414.81% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $2.8 million in 2022, then plummeted by 99.32% to $19000.0 in 2023, then skyrocketed by 468.42% to $108000.0 in 2024, then skyrocketed by 5414.81% to $6.0 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for RXRX at $6.0 million in Q1 2025, $108000.0 in Q1 2024, and $19000.0 in Q3 2023.